Participated · Series A · Jun 2023

Credit Genie is a digital personal finance platform based in Plymouth Meeting, PA. The company says it has served more than one million Americans. It operates under the name Creditly Corp., dba Credit Genie, and is described in the article as a leading digital personal finance platform. Credit Genie announced the completion of an additional funding round securing $10 million in capital. The round was led by Khosla Ventures with participation from Tippet Ventures and brings the company's total financing to $21 million. The article did not disclose further financial details or specific future plans. Credit Genie offers a mobile platform that delivers financial insights and credit-related services by analyzing personal transaction data rather than traditional credit data. From a single app, members get a snapshot of their financial lives and access personalized tips and products to build and improve credit. The platform uses machine learning, AI algorithms and Open AI to identify patterns and predict credit risk, producing more accurate credit scores and improved lending decisions. The company says it will use new funding to expand its product offerings and hire talent. Credit Genie also secured a credit facility to help finance its cash advance and credit card receivables, supporting its operational liquidity. The company was founded by Ed Harycki and operates from Plymouth Meeting, PA.

Participated · Series A · May 2023

Credit Genie operates a mobile financial membership platform that delivers financial alerts and insights, personalized budgeting, and credit-building solutions from a single app. The technology analyzes behavior, chat, and qualitative indicators to produce predictive insights and identify credit risk. Since its 2022 launch the platform has engaged with over 1 million Americans. The company plans to use the new capital to expand its product line and hire talent to scale its behavioral finance, budgeting, and cash/credit management offerings. In connection with the financing it secured a credit facility to finance its cash advance and credit card receivables. Credit Genie was founded by Ed Harycki and is based in Plymouth Meeting, Pa. Credit Genie is a mobile financial membership platform that provides financial alerts, personalized budgeting, credit-building solutions and a 360-degree snapshot of members' finances from a single app. Since its 2022 launch it has engaged more than one million Americans and is headquartered in Plymouth Meeting, Pennsylvania. The platform analyzes personal transaction data plus behavioral, chat and qualitative indicators using home-grown machine learning, AI algorithms and 'Open AI' to predict credit risk and extract financial intent rather than relying on traditional credit data. The company aims to help millions of consumers access efficient credit at fair rates and to create a more inclusive credit system for those often overlooked by mainstream banks. With the new funding Credit Genie plans to expand products and hire talent to scale its behavioral finance, budgeting and cash/credit management offerings. Financially, the company announced a $4 million Series A and has secured a credit facility to finance its cash advance and credit card receivables.

Participated · Equity · May 2023

Dyneval develops a portable, easy-to-use semen analysis tool that the company says produces the most accurate results on the market. The device can produce sex-sorted semen concentrations and assess bull fertility to help predict herd ratios and health. The company says the tool requires no specific training to use. Dyneval secured an additional £500,000 in funding to ramp up production. Management says the funding will help rapidly increase production so the company can serve more farmers across Scotland, the UK and beyond. Leaders framed the product as a way to improve food-production efficiency amid rising costs and tighter access to grant funding. Dyneval has developed the Dynescan, a portable semen-analysis instrument that provides reproducible motility measurements with standard-deviation errors under 3% for samples from the same batch. The device is based on technology developed by soft-matter scientists at Edinburgh, including Wood and Martinez, to characterise complex fluids. Dyneval says the Dynescan will allow vets and farmers to discard damaged or inferior semen before reproduction, reducing repeat inseminations and improving animal welfare and operational efficiency. The company plans to have the Dynescan market-ready in January 2022 and in December 2021 will move to the Roslin Innovation Centre at the University of Edinburgh’s Easter Bush Campus. Dyneval frames the product as addressing falling cattle conception rates and associated environmental benefits, citing models that predict up to a 20% reduction in farming carbon footprint if conception rates improve. Financially, the company has secured grant and equity backing to support product rollout.

Participated · Equity · Dec 2019

Novosound claims to have developed the world’s first ultrasonic blood pressure monitor, enabling cuffless blood pressure monitoring in wearable devices with accuracy comparable to conventional electronic cuff devices. The technology is built on the company’s Slanj platform, which also supports hydration tracking, muscle health assessment, and gesture recognition. Novosound previously collaborated at the Texas Medical Center in Houston and plans to showcase its innovations at CES 2025 in Las Vegas. The company is positioning the technology for global wearable and digital health markets. Novosound recently completed a £2 million funding round to accelerate commercialisation. Par Equity and the company cite plans to accelerate internationalisation and global sales. Novosound, founded in 2018 as a spin-out from the University of the West of Scotland, develops flexible ultrasound sensors capable of continuous operation at high temperatures and delivering higher-resolution images. Its sensors are positioned for both medical imaging and industrial non-destructive testing (NDT) to detect below-surface defects, cracks, or corrosion. The company was established by CTO Dave Hughes and CEO Richard Cooper. In December 2019 Novosound raised funding that it will use to match a £1.0m R&D grant from Scottish Enterprise for product development. Management also plans to use the proceeds to pursue expansion into global markets and new industries. The article does not disclose operating metrics such as revenue or user numbers. Novosound develops hi-tech ultrasound sensors for industrial and medical markets, replacing conventional sensor materials with a flexible piezoelectric thin-film. The company is a spin-out from the University of the West of Scotland and is based at the Biocity incubator outside Glasgow. It secured a £1 million grant from Scottish Enterprise to rapidly scale up R&D and accelerate production activity. Novosound will create 17 new STEM roles, bringing staff to more than 30 and plans to establish a dedicated medical sensors team. The firm previously raised £1.5 million in seed funding in April 2018 from early investors including Par Equity, Kelvin Capital, the Scottish Investment Bank and Investing Women. Management says the technology can produce MR-resolution images at lower cost and highlights a large global ultrasonic market opportunity.

Participated · Seed · May 2019

EnteroBiotix is a clinical-stage biopharmaceutical company focused on full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, is a next-generation full-spectrum microbiome therapeutic manufactured with proprietary processing technologies intended to enable safe, stable, orally delivered microbial ecosystem restoration. The company positions EBX-102-02 as a potential first disease-modifying therapy for IBS-C and advanced the candidate into a Phase 2b program following positive Phase 2a TrIuMPH trial results in 122 patients. The RISE Phase 2b trial is randomized, double-blind, placebo-controlled and plans to enroll around 300 patients in the UK, with first dosing expected in Q2 2026 and topline data due in H2 2027. EnteroBiotix is building a broader pipeline in high-value gastrointestinal indications associated with significant unmet need. EBX-102-02 is not approved for clinical therapeutic use outside of clinical trials or regulated programmes.